Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial.

Authors

Lisa Zimmer

Department of Dermatology, University Hospital, University Duisburg-Essen; German Cancer Consortium (DKTK), Partner Site Essen, Essen, Germany

Lisa Zimmer , Angela Krackhardt , Erwin S. Schultz , Daniela Goeppner , Chalid Assaf , Dietrich Trebing , Elisabeth Livingstone , Dirk Schadendorf

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173).

First Author: Alain Patrick Algazi

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

CTEP #8850: A phase I trial of riluzole and sorafenib in patients with advanced solid tumors.

First Author: Kristen Renee Spencer

insert_chart_outlined

Poster

2023 ASCO Breakthrough

bookmark_border

MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the autophagy inhibitor hydroxychloroquine (HCQ) in KRAS-mutated advanced malignancies.

First Author: Gulam Abbas Manji

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors.

First Author: Adil Daud